Cancer antigen-125 levels predict long-term mortality in chronic obstructive pulmonary disease

• Published in: Biomarkers 2015-03, Vol.20 (2), p.162-167
• Main Authors: Kaya, Hakki, Zorlu, Ali, Yucel, Hasan, Dogan, Omer Tamer, Sarikaya, Savas, Aydin, Gulay, Kivrak, Tarik, Yilmaz, Mehmet Birhan
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Biomarkers - blood; CA-125; CA-125 Antigen - blood; cancer antigen-125; chronic obstructive pulmonary disease; Disease Progression; Female; Humans; Immunoenzyme Techniques - methods; Kaplan-Meier Estimate; long-term mortality; Lung - pathology; Lung - physiopathology; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Pulmonary Disease, Chronic Obstructive - blood; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - mortality; Respiratory Function Tests; Risk Assessment - methods; Risk Assessment - statistics & numerical data; Risk Factors; risk stratification; Survival Rate; Time Factors
• ISSN: 1354-750X; 1366-5804
• DOI: 10.3109/1354750X.2015.1045033

Abstract Background: Cancer antigen-125 (CA-125) might be a useful biomarker to predict long-term mortality in patients with recent exacerbation of chronic obstructive pulmonary disease (COPD). Methods: A total of 87 consecutive patients with COPD were evaluated prospectively. Mean age of patients was 68 ± 10 years (55% males, 45% females) with a median follow-up period of 49 months. Optimal cut-off value of CA-125 to predict mortality was found as >93.34 U/ml, with 91% specificity and 40% sensitivity. Results: After follow-up, 20 out of 87 (23%) experienced cardiovascular death. CA-125 levels were higher among those who died compared to those who survived [55 (12-264) versus 28 (5-245) U/ml, p = 0.013]. In multivariate Cox proportional-hazards model with forward stepwise method, only CA-125 > 93.34 U/ml on admission (HR = 3.713, 95% CI: 1.035-13.323, p = 0.044) remained associated with an increased risk of death. Conclusions: For the first time, we demonstrated that CA-125 helps the risk stratification of patients with COPD.